| scholarly article | Q13442814 |
| P50 | author | Joseph Sodroski | Q64524473 |
| P2093 | author name string | James E Robinson | |
| Shi-Hua Xiang | |||
| Najah Doka | |||
| Rabeéa K Choudhary | |||
| P2860 | cites work | Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS) | Q22242256 |
| Identification of a major co-receptor for primary isolates of HIV-1 | Q22251282 | ||
| P433 | issue | 16 | |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 1207-1217 | |
| P577 | publication date | 2002-11-01 | |
| P1433 | published in | AIDS Research and Human Retroviruses | Q4651880 |
| P1476 | title | Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies | |
| P478 | volume | 18 |
| Q28553032 | A Cinnamon-Derived Procyanidin Compound Displays Anti-HIV-1 Activity by Blocking Heparan Sulfate- and Co-Receptor- Binding Sites on gp120 and Reverses T Cell Exhaustion via Impeding Tim-3 and PD-1 Upregulation |
| Q35569049 | A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses |
| Q54216786 | A novel strategy to adapt SHIV-E1 carrying env from an RV144 volunteer to rhesus macaques: coreceptor switch and final recovery of a pathogenic virus with exclusive R5 tropism |
| Q38350707 | A synthetic CD4-heparan sulfate glycoconjugate inhibits CCR5 and CXCR4 HIV-1 attachment and entry. |
| Q37033400 | Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals |
| Q36878885 | Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds |
| Q36141515 | Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens |
| Q37333772 | Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors |
| Q36403587 | Antigenic conservation and immunogenicity of the HIV coreceptor binding site |
| Q27320687 | Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells |
| Q39081549 | Antigenic variations in the CD4 induced sites of the CCR5‐tropic, pathogenic SHIVsf162p3 gp120 variants |
| Q91621750 | Asymmetric opening of HIV-1 Env bound to CD4 and a coreceptor-mimicking antibody |
| Q33657941 | Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates |
| Q35973601 | Blockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells |
| Q37261545 | Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition |
| Q36104987 | Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env. |
| Q38437455 | CD4-Induced Antibodies Promote Association of the HIV-1 Envelope Glycoprotein with CD4-Binding Site Antibodies. |
| Q37730009 | CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor |
| Q33743734 | CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies |
| Q81075242 | Characterization of antibodies that inhibit HIV gp120 antigen processing and presentation |
| Q37072702 | Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. |
| Q35913921 | Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1 |
| Q52721542 | Comparison of Uncleaved and Mature Human Immunodeficiency Virus (HIV-1) Membrane Envelope Glycoprotein Trimers. |
| Q41610618 | Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains |
| Q36827348 | Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors |
| Q38793711 | Crosslinking of a CD4 Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques |
| Q33788810 | Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains |
| Q38962226 | Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope |
| Q27675486 | Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding |
| Q28732438 | Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein |
| Q35076987 | Enzyme Digests Eliminate Nonfunctional Env from HIV-1 Particle Surfaces, Leaving Native Env Trimers Intact and Viral Infectivity Unaffected |
| Q40621073 | Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains |
| Q33504599 | Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways |
| Q33558696 | Evaluation of CD4-CD4i antibody architectures yields potent, broadly cross-reactive anti-human immunodeficiency virus reagents |
| Q37346068 | Expression of Human Immunodeficiency Virus Type 1 Neutralizing Antibody Fragments Using Human Vaginal Lactobacillus. |
| Q24672335 | Frequent intrapatient recombination between human immunodeficiency virus type 1 R5 and X4 envelopes: implications for coreceptor switch |
| Q33780450 | Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody |
| Q35140032 | Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa |
| Q33719511 | Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies |
| Q36276274 | HIV-1 Neutralizing Antibodies Display Dual Recognition of the Primary and Coreceptor Binding Sites and Preferential Binding to Fully Cleaved Envelope Glycoproteins |
| Q39402539 | HIV-1 Virus-Like Particles Bearing Pure Env Trimers Expose Neutralizing Epitopes but Occlude Nonneutralizing Epitopes |
| Q64934974 | HIV-1 autoreactive antibodies: are they good or bad for HIV-1 prevention? |
| Q37179996 | Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India |
| Q45463275 | Highly conserved beta16/beta17 beta-hairpin structure in human immunodeficiency virus type 1 YU2 gp120 is critical for CCR5 binding |
| Q36863847 | Humoral immunity to HIV-1: neutralization and beyond. |
| Q39668082 | Identification and characterization of an immunogenic hybrid epitope formed by both HIV gp120 and human CD4 proteins |
| Q47566053 | Identification of novel structural determinants in MW965 Env that regulate the neutralization phenotype and conformational masking potential of primary HIV-1 isolates |
| Q35708836 | Identifying epitopes of HIV-1 that induce protective antibodies |
| Q35171701 | Immunization of rabbits with highly purified, soluble, trimeric human immunodeficiency virus type 1 envelope glycoprotein induces a vigorous B cell response and broadly cross-reactive neutralization |
| Q30401836 | Induction of a Tier-1-like Phenotype in Diverse Tier-2 Isolates by Agents that Guide HIV-1 Env to Perturbation-sensitive, Non-native States |
| Q33614605 | Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates |
| Q40468582 | Inter-subunit disulfide bonds in soluble HIV-1 envelope glycoprotein trimers. |
| Q34885869 | Isolate-Specific Differences in the Conformational Dynamics and Antigenicity of HIV-1 gp120 |
| Q34306877 | Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop |
| Q33683203 | Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and Macaques |
| Q34347265 | Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein |
| Q37010852 | N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies |
| Q30524110 | Neutralization Resistance of Virological Synapse-Mediated HIV-1 Infection Is Regulated by the gp41 Cytoplasmic Tail |
| Q40909337 | Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection |
| Q27490987 | Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient |
| Q35857268 | Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection |
| Q57283084 | Partially Open HIV-1 Envelope Structures Exhibit Conformational Changes Relevant for Coreceptor Binding and Fusion |
| Q47109778 | Patterns of conserved gp120 epitope presentation on attached HIV-1 virions |
| Q24635002 | Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals |
| Q43432407 | Potency of HIV-1 envelope glycoprotein gp120 antibodies to inhibit the interaction of DC-SIGN with HIV-1 gp120. |
| Q33821896 | Probing the Impact of Local Structural Dynamics of Conformational Epitopes on Antibody Recognition |
| Q36974754 | Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. |
| Q33778466 | Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution |
| Q37460580 | Protective versus pathogenic anti-CD4 immunity: insights from the study of natural resistance to HIV infection |
| Q40325417 | Quaternary contact in the initial interaction of CD4 with the HIV-1 envelope trimer |
| Q39610645 | Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4 |
| Q36811996 | Range of CD4-Bound Conformations of HIV-1 gp120, as Defined Using Conditional CD4-Induced Antibodies |
| Q34174815 | Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36. |
| Q30353580 | Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1 |
| Q36837815 | Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization |
| Q39723388 | Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization |
| Q34397758 | Sequences in Glycoprotein gp41, the CD4 Binding Site, and the V2 Domain Regulate Sensitivity and Resistance of HIV-1 to Broadly Neutralizing Antibodies |
| Q27675475 | Shape change in the receptor for gliding motility in Plasmodium sporozoites |
| Q40263167 | Single N277A substitution in C2 of simian immunodeficiency virus envelope influences vaccine-elicited CD4i neutralizing and anti-V2 antibody responses. |
| Q47554821 | Single-Domain Antibodies As Therapeutics against Human Viral Diseases |
| Q37084521 | Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses |
| Q35857416 | Stability of a receptor-binding active human immunodeficiency virus type 1 recombinant gp140 trimer conferred by intermonomer disulfide bonding of the V3 loop: differential effects of protein disulfide isomerase on CD4 and coreceptor binding |
| Q35065249 | Stabilization of HIV-1 Envelope in the CD4-bound Conformation through Specific Cross-linking of a CD4 Mimetic |
| Q28534454 | Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein |
| Q61816156 | Structural Basis for Epitopes in the gp120 Cluster A Region that Invokes Potent Effector Cell Activity |
| Q27640572 | Structural Definition of an Antibody-Dependent Cellular Cytotoxicity Response Implicated in Reduced Risk for HIV-1 Infection |
| Q27643185 | Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120 |
| Q27683553 | Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers |
| Q36856960 | Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors |
| Q27660384 | Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity |
| Q34485260 | The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter |
| Q40968142 | The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120. |
| Q36957295 | The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors |
| Q40051843 | The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen |
| Q28275986 | The good and evil of complement activation in HIV-1 infection |
| Q33614365 | Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies |
| Q37431843 | Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity |
| Q37333789 | Transitions to and from the CD4-bound conformation are modulated by a single-residue change in the human immunodeficiency virus type 1 gp120 inner domain |
| Q44530442 | Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. |
| Q34203163 | Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection |
| Q35192660 | epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals |
| Q33348658 | sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates |
Search more.